Abstract
The development of treatment biomarkers for psychiatric disorders has been challenging, particularly for heterogeneous neurodevelopmental conditions such as attention-deficit/hyperactivity disorder (ADHD). Promising findings are also rarely translated into clinical practice, especially with regard to treatment decisions and development of novel treatments. Despite this slow progress, the available neuroimaging, electrophysiological (EEG) and genetic literature provides a solid foundation for biomarker discovery. This article gives an updated review of promising treatment biomarkers for ADHD which may enhance personalized medicine and novel treatment development. The available literature points to promising pre-treatment profiles predicting efficacy of various pharmacological and non-pharmacological treatments for ADHD. These candidate predictive biomarkers, particularly those based on low-cost and non-invasive EEG assessments, show promise for the future stratification of patients to specific treatments. Studies with repeated biomarker assessments further show that different treatments produce distinct changes in brain profiles, which track treatment-related clinical improvements. These candidate monitoring/response biomarkers may aid future monitoring of treatment effects and point to mechanistic targets for novel treatments, such as neurotherapies. Nevertheless, existing research does not support any immediate clinical applications of treatment biomarkers for ADHD. Key barriers are the paucity of replications and external validations, the use of small and homogeneous samples of predominantly White children, and practical limitations, including the cost and technical requirements of biomarker assessments and their unknown feasibility and acceptability for people with ADHD. We conclude with a discussion of future directions and methodological changes to promote clinical translation and enhance personalized treatment decisions for diverse groups of individuals with ADHD.
Similar content being viewed by others
Introduction
Biomarker discovery for psychiatric disorders and symptoms has been challenging, despite a clear need to guide clinical decisions [1,2,3] and a vast literature examining neurobiological underpinnings of diagnoses, dimensional constructs (i.e., Research Domain Criteria [RDoC]) [4, 5], developmental trajectories [6, 7], and treatment response [8, 9]. Furthermore, promising findings are rarely translated to clinical practice, in academic medical hospitals or clinics or even further, to community clinical settings. This has been true for nearly all psychiatric disorders, yet particularly true for neurodevelopmental disorders such as attention-deficit/hyperactivity disorder (ADHD), which is likely to have multiple etiological and neurobiological pathways and whose benchmarks for “typical” and “pathological” are moving targets due to population-level variability in behavioral, cognitive, and brain maturation rates [3, 10]. The lack of biomarker translation is especially evident in the slow development of novel treatments for ADHD (and many other disorders) [11], where the gold-standard of treatment, psychostimulant medications, has been the same for over 50 years. Despite the slow progress, the considerable scientific efforts and substantial literature base provide a promising foundation for biomarker discovery. The goal of this article is to give an updated narrative review of promising biomarkers for ADHD treatment response along with methodological changes that may assist with clinical translation to enhance personalized medicine and novel treatment development.
We first briefly discuss biomarker definitions and categories to provide a framework for the review. In 2001, the NIH Biomarkers Definitions Working Group defined a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathologic processes, or biological responses to a therapeutic intervention. A biomarker can be a physiologic, pathologic, or anatomic characteristic or measurement that is thought to relate to some aspect of normal or abnormal biologic function or process” [12]. While there have been several variants on this basic theme, particularly as applied to various biomarkers of types (e.g., blood biomarkers) and disease states (e.g., cancer biomarkers or psychiatric biomarkers), a recent outline of biomarker categories by the Food and Drug Administration (FDA) Biomarkers, EndpointS and other Tools (BEST) [13] Resource will be used as a framework for the current review (Fig. 1). Literature on diagnostic and susceptibility/risk biomarkers are outside the scope of this paper (recent reviews can be found elsewhere [3, 14,15,16]). We thus focus on categories relevant to treatment decision making (i.e., predictive and monitoring/ response biomarkers). We highlight key findings by providing examples from strong, methodologically rigorous studies, particularly on pharmacological treatments, along with methodological barriers to clinical translation.
Predictive biomarkers
Given the wide variability in effectiveness and tolerability of available treatments, an important motivation for developing biomarkers has been to identify measures parsing this variability and aiding personalized treatment decisions. This is especially needed for treatments such as non-stimulants and non-pharmacological options, where effects may not be observed until weeks after treatment initiation. Here, we use the term “predictive biomarkers” based on BEST guidelines [13] (Fig. 1), but recognize that studies have also referred to these measures as “prognostic biomarkers” [17].
Structural and functional neuroimaging
Pre-treatment subcortical volumes have been associated with treatment response to methylphenidate (MPH), with responders showing smaller volumes than non-responders [18] in one study but greater gray matter concentration [19] in another study (Table 1). A single study using diffusion-weighted imaging found that a machine learning algorithm could predict better MPH response from higher values of local efficiency (reflecting how efficiently information can be distributed between a brain region and its neighbors) within the thalamus, precentral gyrus and superior frontal gyrus [20]. Although the directions of the patterns are mixed, measures implicated in the pathophysiology of ADHD have been found to have potential predictive value with treatment effects.
With regard to functional MRI, studies have shown that greater left lateral prefrontal cortex activation during a Stroop task [21] and age-related increases in within-network cingulo-opercular connectivity tracking the developmental trajectory of neurotypical controls [22] were associated with improvement in ADHD symptoms as assessed while subjects were on versus off medication. One of these studies in particular suggests that predictive biomarkers of treatment response may be developmentally sensitive, requiring repeated assessments of developmental change [22]. Importantly, both studies used naturalistic, observational designs of chronically medicated youth scanned off medication, and may not generalize to very poor treatment responders, who are more likely to cease treatment [21, 22]. Moreover, since long-term medication exposure may produce changes in brain patterns, findings may not apply to individuals assessed prior to treatment [23]. These issues can be overcome by clinical trials. In one such study, lower pre-treatment connectivity from striatal regions to orbitofrontal, cingulo-opercular and middle and medial temporal regions was associated with better treatment outcomes after 8-week MPH treatment [24]. Studies have further tested whether acute changes (particularly with short-acting psychostimulants) may predict symptom improvement over longer timeframes [22]. To our knowledge, only one fMRI study has adopted such a design in a small sample (N = 7), reporting that greater decreases in regional homogeneity (i.e., local coherence in fluctuating BOLD signals, or local connectivity) within right postcentral gyrus and superior parietal lobe following a single MPH dose predicted lower ADHD severity at 8 weeks [25].
While most studies focused on a single form of treatment, neuroimaging profiles predicting differential response to different treatments may be more useful to guide treatment decisions at the individual level (i.e., treatment stratification [26]). A notable study of this type, using a double-blind, cross-over randomized controlled design comparing 8-week MPH vs. atomoxetine (ATX) treatment, found that greater pre-treatment caudate activation predicted better treatment response to MPH, but worse response to ATX [27]. These findings suggest that the identified fMRI patterns, if replicated, may be valuable for predicting response to different treatments.
In addition to potential applications in treatment allocation algorithms, an aim of biomarker research is to develop novel neurotherapies targeting neural processes associated with a disorder or modulated by existing treatments [11]. The most elegant neuroimaging example is provided by studies investigating fMRI neurofeedback of the right inferior frontal gyrus (IFG) as a novel ADHD treatment [28,29,30], guided by meta-analytic evidence that the right IFG is under-activated in individuals with ADHD [31, 32], but upregulated by ADHD medications [9, 31, 32]. Although clinical improvements over 2 weeks were observed both with rIFG-neurofeedback and a control neurofeedback condition (para-hippocampal region), only active rIFG-neurofeedback showed evidence of improvements in everyday life (i.e., learning retention) after 11 months [28]. Individual differences in neurofeedback learning were associated with greater pre-treatment inferior frontal and striatal activation during an inhibitory control task [29].
Overall, while the ability of single pre-treatment brain scans to guide clinical decision making is an important goal, the current neuroimaging literature does not point to any immediate clinical applications of neuroimaging biomarkers due to inconsistent findings and small sample sizes (Table 1). Further, the high costs, contraindications and low tolerance of participants’ movement of MRI are considerable barriers to the future implementation of neuroimaging biomarkers in clinical settings (particularly for highly hyperactive children), and will require substantial methodological innovation (e.g., shorter scans, better motion corrections). Finally, the methodology for testing promising findings as predictive biomarkers must evolve to be clinically useful. For example, the right IFG-neurofeedback findings [28,29,30] should be quantified for a threshold value (of activation) that maximally identifies treatment response, and then that value should be used as an inclusion criterion or to stratify participants in subsequent independent prospective trials to determine its predictive validity. This last step has not been implemented in any neuroimaging studies of predictive biomarkers to date but is necessary to develop a biomarker that can be used by others in clinical settings.
EEG
EEG has been one of the main techniques to investigate the neural mechanisms of ADHD treatment response [8, 33]. Compared to fMRI, EEG recordings allow the direct investigation of brain activity with greater temporal resolution, but less accurate spatial precision [1, 17]. EEG is also less expensive and more tolerant of participants’ movement, making it easier to collect large clinical samples over time for the development of treatment biomarkers [34].
The most consistent findings suggest that higher spectral power in the theta band (4–7 Herz [Hz]) during resting states (eyes open or closed) is associated with better clinical outcomes following stimulant treatment [17, 35, 36] (Table 2). A common interpretation of this finding is that lower pre-treatment levels of arousal and vigilance, commonly displayed by children with ADHD [37], predict better response. In some studies, excess theta power in responders was accompanied by lower power in faster frequencies, especially beta (generally 13–25 Hz), and elevated theta-to-beta-ratio (TBR) [35, 36]. Yet, an association between TBR and treatment outcome was not replicated in a larger, more recent study [38], suggesting that TBR may have questionable predictive utility, besides its well-documented limited diagnostic properties [39, 40]. Further, event-related potential (ERP) studies found that more intact auditory P3 [41], cue P3 and contingent negative variation [36, 42] amplitudes, reduced no-go P3 amplitudes [36, 42], and greater change in P3 amplitude after a single stimulant dose predicted better stimulant response [42, 43]. Two notable studies also tested the combined predictive effects of spectral power and ERPs on treatment response [36, 42], accounting for shared variance between various measures. In a multivariate model, higher cue P3, smaller no-go P3, and excess theta power were the only significant predictors of stimulant response [36]. An aggregate index combining EEG/ERP and performance measures predicted treatment response with 88% specificity and 86% sensitivity [42].
Fewer studies focused on non-stimulant medications. A 12-month study of ATX found broad pre-treatment increases in power in children classified as non-responders relative to controls, whereas responders only showed elevations in slower frequencies such as the delta (<4 Hz), theta and alpha (8–12 Hz) bands [44]. Lower pre-treatment N2 amplitudes [45] and greater pre-treatment P3 amplitudes [41, 46] during auditory tasks have been associated with better response after 6–10 weeks of ATX treatment, although non-significant P3 effects were also reported [45]. Both in children and in adults, greater change in temporo-parietal theta cordance (a measure of regional spectral power) at 1 week predicted clinical outcomes at 6–12 weeks [47, 48].
Although most available studies of EEG predictive biomarkers have investigated pharmacological treatments, a notable non-pharmacological example is a novel 4-week double-blind, sham-controlled trigeminal nerve stimulation (TNS) trial, where lower pre-treatment resting-state right-frontal theta and alpha power predicted greater clinical improvement [49]. Furthermore, EEG power, coupled with deficits on a behavioral rating of executive functioning, had an area under the curve (AUC) of 0.81, suggesting good prediction of TNS treatment response. Since these findings come from the first RCT testing TNS for ADHD, replication in future larger trials is needed. Another non-pharmacological study [50] found that, compared to non-remitters, girls and women whose ADHD symptoms remitted following quantitative EEG-informed neurofeedback showed shorter frontal P3 latencies during an auditory task, whereas boys and men who remitted had lower individual alpha peak frequency (iAPF; i.e., the frequency at which an individual’s alpha activity oscillates, with slower profiles potentially reflecting reduced thalamo-cortical information flow [51, 52]). Given the relatively inconclusive evidence on neurofeedback efficacy for ADHD at the group level [53,54,55], these studies may help to identify biologically-distinct ADHD subgroups who respond better to this treatment.
Only a few studies tested EEG predictors of more than one type of treatment [52, 56, 57]. An 8-week randomized controlled trial (RCT) comparing MPH, guanfacine and their combination found that event-related EEG power profiles during a working memory task showed treatment-specific associations with clinical improvements [57]. Specifically, better treatment outcome was predicted by weaker mid-frontal beta power modulations localized in the anterior cingulate cortex (ACC) in children treated with combined MPH + guanfacine, but by stronger modulations in children treated with MPH or guanfacine. Together, EEG measures explained twice as much variance in treatment outcome than clinical measures alone in children treated with guanfacine and combined treatments. These findings, while awaiting replication in independent samples, suggest that EEG profiles could supplement clinical information to aid future personalized treatment decisions.
Another noteworthy exemplar based on different treatments is a recent multi-sample study of iAPF [52]. Guided by previous literature showing associations of slow iAPF with worse stimulant response [38, 58] but better neurofeedback response [50], particularly in boys and men, this study tested whether iAPF differentially predicted ADHD remission following MPH and multimodal neurofeedback treatments in boys with ADHD [52]. After developing and validating iAPF as a neurobiologically plausible biomarker in a large transdiagnostic sample, this study found that iAPF was able to stratify children with ADHD to MPH (high iAPF) or multimodal neurofeedback (low iAPF) with gains in remission of 17–30% relative to observed remission rates. These results were corroborated in blinded, out-of-sample validations, with predictive gains of 29–36%. Additional exploratory analyses showed that iAPF predicted remission to guanfacine (high iAPF) and ATX (low iAPF). These findings point to iAPF as a robust biomarker able to predict treatment outcome across independent samples. As stated above for neuroimaging biomarkers, an important next step to inform future personalized treatment approaches would be to carry out a prospective study using iAPF to stratify individuals with ADHD to different treatments.
To summarize, while most of the EEG profiles predicting treatment outcomes have been examined only for stimulants, right frontal resting state spectral power, event-related power related to working memory and iAPF emerge as candidate predictive biomarkers that may aid future stratification and prediction of response to different treatments. Future studies will need to apply out-of-sample stratification and validation approaches prospectively to a wider portion of the ADHD population, treatments and EEG profiles.
Genetics
Genetic studies have also investigated biomarkers predicting treatment response, particularly to MPH (Table 3). The first wave of studies took a candidate gene approach focused on single nucleotides polymorphisms (SNPs) and variable number tandem repeat (VNTR) within or proximal to monoaminergic genes [59, 60], as ADHD medications act on dopaminergic, serotonergic and adrenergic systems. A meta-analysis found that many candidate variants predicted MPH response with odds ratios (ORs) around 1.5–3 [60], including a VNTR within the SLC6A3 gene encoding the dopamine transporter, SNPs tagging the gene coding for the norepinephrine transporter (SLC6A2), variants within the DRD4 gene altering receptor expression and near the ADRA2 gene coding for the alpha-2-adrenergic receptor, and a SNP within the enzyme Catechol-o-methyltransferase (COMT) involved in degrading catecholamines.
Given the known limitations of candidate gene approaches [61], more recent work has focused on genome-wide association studies (GWAS). As large sample sizes are needed in GWAS of complex phenotypes such as medication response, studies including less than 250 participants found no genome-wide significant SNPs tied to medication response [62, 63]. More promising results come from a large Danish study that linked genotype data with medical records, allowing a well-powered GWAS of starting (N = 7427) or stopping (N = 3370) MPH treatment or switching to non-stimulants (N = 1137) over 2 years [64]. While no genome-wide significant associations emerged for starting or stopping treatment, a locus on 16q23.3 containing genes associated with many neuropsychiatric phenotypes was associated with switching medications, likely due to poor efficacy. In addition to common genetic variants, a few studies have examined rarer genetic variants, such as copy number variants (CNVs; these represent large scale genomic duplications or deletions). One study reported that ADHD-associated CNVs were concentrated in genes within a network of metabotropic glutamate receptor genes, affecting 11.3% of ADHD cases compared to 1.2% of neurotypical controls [65]. In a subsequent open-label trial, individuals who harbored CNVs within this glutamatergic gene network had better therapeutic response to an activator of this glutamate receptor, fasoracetam [66].
Since each individual genetic marker only explains a tiny fraction of treatment response, three studies have investigated aggregate measures of genetic risk using polygenic risk scores (PRS) (i.e., the sum of alleles across the genome weighted by their effect size). PRS for ADHD was found to predict a favorable response to ADHD medication (MPH or ATX), explaining around 2% of the variance [63]. The aforementioned Danish study did not find the PRS for ADHD to be associated with treatment outcomes [64], consistent with recent evidence that genes implicated in the pathogenesis of ADHD do not overlap with genes encoding targets of stimulants and ATX [67]. However, PRS for bipolar disorder and schizophrenia increased the likelihood of stopping stimulant medication (~5–7% of the variance) [64], mirroring findings that comorbid bipolar or psychotic disorders are associated with poor treatment response and adverse events. Finally, a PRS for MPH response derived in a childhood cohort did not significantly predict response in an independent adult cohort [62], with several interesting nominally significant signals that may be worthy of future exploration.
Additionally, there has been interest in genetic markers that lie within the cytochrome P450 superfamily of enzymes. The cytochrome P450 system largely determines the metabolism of ATX and varies widely between individuals by genotype, and by race and ethnicity [68]. Pharmacokinetic genetic studies have particularly focused on the cytochrome P450,2D6 (CYP2D6), contrasting individuals with different genotypes leading to ultrarapid, extensive and poor metabolism of ATX. Poor metabolizers show up to 9 times less plasma clearance of ATX than the extensive metabolizers, creating greater exposure to the drug. In turn this raises the question of whether dosage adjustment based on CYP2D6 genotype may help avoid adverse side effects, at least for those taking high doses of ATX.
Together, initial findings suggest that stratifying individuals based on genetic markers, such as PRS and CNVs, may be useful to guide future treatment choice in a mechanistic manner. Future studies will need to use much larger samples, consider possible multiplicative effects of different genetic markers, investigate the effects of genetic biomarkers on response to multiple pharmacological and non-pharmacological treatments, and test the predictive utility of genetic biomarkers in combination with other biomarkers, such as the promising neuroimaging and EEG biomarkers discussed above.
Monitoring and response/pharmacodynamic biomarkers
Another major application of treatment biomarkers is for treatment monitoring, with repeated biomarker assessments performed before and after treatment, in response to acute doses or over longer periods. Neuroimaging and EEG biomarkers reviewed in this section are consistent with the BEST monitoring biomarker category and response/pharmacodynamic biomarker category [13] (also sometimes called “pharmacokinetic biomarkers”) (Fig. 1).
Structural and functional neuroimaging
Both acute and longer-term treatment effects on brain patterns have been documented using structural and functional magnetic resonance imaging in ADHD samples (Table 4). Changes in structural neuroimaging markers following treatment with MPH have been studied as part of a 16-week double-blind, randomized, placebo-controlled trial of boys and young men with ADHD [69, 70]. One report from this trial showed wide-spread time-by-medication-by-age interaction effects in left hemisphere white matter, which were driven by increases in fractional anisotropy among medicated children [69]. A report from the same trial described increasing cortical thickness in medicated children within right medial frontal cortex, which contrasted with the cortical thinning that was observed in the placebo group. No significant results were found for the adult groups, and structural brain changes were not associated with clinical improvement [70]. Similarly, a double-blind randomized placebo-controlled trial of N = 131 adults with ADHD who underwent 12 months of MPH treatment reported no significant treatment-related changes in gray matter volume [71].
A reasonably large literature, including studies using double-blind placebo-controlled designs in unmedicated youth with ADHD, has examined changes in brain functioning under acute doses of stimulant medication [9, 72,73,74,75] (Table 4). Available fMRI studies reported upregulation of cingulo-opercular [9, 73, 76, 77] and striato-thalamic activation [9, 77], and greater default mode deactivation [9, 21, 78] across a range of cognitive tasks. Regarding resting-state fMRI, changes in brain functioning following acute doses have also been reported in cingulo-opercular, striato-thalamic and default mode networks [25, 79,80,81]. However, results are more varied than those from the task-based literature, arguably reflecting the heterogeneity in processing pipelines, regions of interest, network parcellations and imaging metrics [81]. Nonetheless, two recent studies have converging findings which point to a stabilizing influence of psychostimulants on atypically variable resting-state connectivity patterns in subjects with ADHD, as assessed using dynamic functional connectivity methods [82, 83]. The few studies investigating acute non-stimulant (e.g., ATX) effects have reported largely overlapping patterns of functional brain changes to those seen under single MPH doses [73,74,75], despite the longer time needed for ATX to produce therapeutic effects and its distinct molecular mechanisms [84].
A further body of work has examined the links between treatment-related improvements in ADHD symptoms and pre- to post-treatment changes in brain functioning over the course of clinical trials. ADHD symptom changes have been associated with changes in functional connectivity between bilateral medial frontal and left insular regions [85] and in fractional amplitude of low-frequency fluctuations (fractional ALFF) within bilateral superior parietal lobe [86]. Studies on ATX suggest that the therapeutic mechanisms of ATX require medium-term changes in the brain [87, 88], and that ATX-related improvements in ADHD symptoms were related to changes in functional connectivity, predominantly involving inferior frontal and temporo-parietal regions [87]. Interestingly, initial studies directly comparing the medium-to-long term effects of MPH and ATX on brain functioning suggest partly different effects [88, 89]. For example, in one study, clinical improvements positively correlated with treatment-related increases in fractional ALFF within left temporo-parietal and bilateral pre- and post-central gyri regions for participants taking MPH, but negatively with changes in fractional ALFF within left occipital lobe and pre- and post-central gyri for patients taking ATX [88]. Regarding task-based fMRI, one medium-term (6–8 weeks) study reported that improvement in symptoms were associated with gains in task-related activation for ATX but reductions in activation for MPH in the right IFG, left anterior cingulate/supplementary motor area, and bilateral posterior cingulate cortex [89].
With regard to non-pharmacological interventions, the aforementioned fMRI neurofeedback trial of the rIFG represents a notable example [30, 90]. The IFG-neurofeedback group showed increases in fronto-striatal activation during an inhibitory control task and in activation and connectivity during a learning transfer test from pre- to post-treatment, which correlated with ADHD symptom improvements [28,29,30, 90].
Together, these findings provide initial evidence suggesting that distinct neuroimaging biomarkers may be useful for monitoring the longer-term effects of MPH, ATX and right IFG-neurofeedback (fronto-striatal activity/connectivity). Nevertheless, limitations of this body of work include reliance of small sample sizes and lack of replications, as well as more practical limitations of MRI which limit its utility in clinical settings.
EEG
Several studies have investigated the acute effects of medication on EEG profiles in individuals with ADHD [8] (Table 5). Acute MPH doses decrease theta and alpha power and increase beta power [91, 92] during resting states, suggesting that acute stimulants ameliorate patterns of cortical hypo-arousal associated with ADHD [92]; although non-significant [93, 94] effects have also been reported. Acute MPH administration also increases the amplitude of ERP components often reduced in individuals with ADHD [16, 95], such as P3 [96, 97] and error-related negativity and positivity [98] during go/no-go tasks, whereas effects on N2 amplitudes are more mixed [96, 97]. These partly inconsistent findings likely arise from the use of small, heterogeneous samples and analytic differences (e.g., use of absolute vs. relative power). Initial findings further suggest that acute ATX doses decrease spectral power in delta, theta and beta bands [99].
Studies investigating the longer-term effects of pharmacological treatment on EEG data have generally shown that stimulants ameliorate EEG patterns that differ between individuals with ADHD and neurotypical controls [16, 100,101,102], albeit often without reaching full normalization. MPH treatment have been shown to increase resting-state beta power and reduce theta power and TBR across several studies [8, 103,104,105,106], particularly over frontal and central scalp regions, although non-significant effects have also been reported, [106,107,108,109] especially for TBR [8]. Regarding event-related activity, stimulants have consistently shown medium and long-term effects on ERP components associated with impaired sustained attention and cognitive control in individuals with ADHD, particularly for P3 amplitudes [107, 110,111,112,113], with P3 increases linked with improvements in clinical and cognitive profiles [111].
Besides EEG studies of stimulants, 12-month ATX treatment produced decreases in EEG resting-state power in delta, theta, and alpha bands in responders but no changes in non-responders [44]. Several studies have also focused on EEG effects of non-pharmacological treatments. Preliminary but encouraging data exist from a 4-week RCT of trigeminal nerve stimulation in children with ADHD, showing that active treatment increased resting state right-frontal (delta, theta, beta, and gamma) and mid-frontal (gamma) spectral power [114]. Several studies have reported effects of neurofeedback, although findings appear quite inconsistent [56, 103, 110, 115]. More generally, the utility of neurofeedback biomarkers remains unclear given the inconclusive findings on the clinical efficacy of neurofeedback [53,54,55].
Very few EEG studies have compared the effect of different treatments on EEG measures. While similar acute effects of MPH and ATX have been reported on EEG spectral power [116], a cross-over study comparing the effects of 8-week MPH vs. ATX on contingent negative variation amplitudes showed increases with MPH but not ATX [117]. Only one RCT, to our knowledge, compared the long-term effects of stimulant medication (MPH), non-stimulant medication (guanfacine, an alpha-2 agonist) as well as their combination [109, 118]. After 8 weeks, each treatment displayed distinct effects on resting-state spectral power and event-related power during a spatial working memory (WM) task. MPH was associated with increased centro-parietal resting-state beta power and mid-occipital event-related theta power during WM retrieval, which was localized in the primary visual cortex. Guanfacine decreased resting-state alpha power across scalp regions and mid-occipital alpha power during working memory maintenance and retrieval (although event-related findings did not survive multiple-testing corrections). Combined MPH + guanfacine treatment increased centro-parietal resting-state beta power, decreased resting-state theta power across scalp regions, and decreased event-related mid-occipital theta and beta power throughout the WM task, suggesting ameliorating effects on EEG measures showing ADHD-control differences in previous studies [100, 101, 119, 120]. Changes in EEG activity produced by combined medication were also associated with significant clinical and cognitive improvements [109, 118]. Finally, a few notable studies have directly compared the effects of medication and non-pharmacological interventions on EEG measures. In an RCT testing the effects of MPH, neurofeedback and physical activity, the former two treatments showed comparable reductions in theta power and smaller reductions with physical activity [103]. Yet, only MPH increased P3 amplitudes during a go/no-go task compared with neurofeedback and physical activity [110]. These differences were no longer evident after 6 months, suggesting similar long-term effects of these treatments [121].
Overall, findings reviewed here suggests that EEG profiles, particularly event-related measures (e.g., P3 amplitudes and event-related power modulations), are promising monitoring biomarkers. Future studies should replicate these encouraging findings in more heterogeneous samples and test the effects of multiple treatments. The application of source localization techniques is particularly promising for uncovering underlying brain mechanisms of EEG biomarkers and may also guide the development of novel non-pharmacological treatments [1].
Discussion
In this article we have reviewed progress in the discovery of treatment biomarkers for ADHD and their translation towards personalized treatment approaches, with a particular focus on predictive and monitoring/response biomarkers. Several pre-treatment profiles have been shown to predict response to pharmacological treatments for ADHD, with more preliminary but encouraging findings for response to non-pharmacological treatments. The most promising measures for treatment prediction are EEG measures such as iAPF and event-related beta power modulations, and genetic markers involved in PRS and CNVs, whereas the MRI literature has generally yielded more mixed findings largely based on small samples. These pre-treatment profiles represent candidate predictive biomarkers which, in the future, may assist in the stratification of patients with ADHD to specific treatments. Research leveraging repeated biomarker assessments further suggests that clinical response to ADHD treatments is underpinned by treatment-specific changes in brain profiles. These treatment-related changes have typically been consistent with the amelioration of neural patterns that are altered in children and adults with ADHD, although some evidence of “better than typical” post-treatment profiles have also been reported, suggesting potential compensatory mechanisms [118, 122]. These findings point to promising candidate monitoring/response biomarkers which may not only assist in future monitoring of treatment response, but also guide development of novel treatments (e.g., neurotherapeutics [11]) targeting neurobiological mechanisms.
Overall, this body of research represents a solid research base for the development of biomarker approaches and for the future allocation of patients to existing and novel pharmacological and non-pharmacological treatments based on their individual behavioral and neurobiological profiles, consistent with the principles of precision and personalized medicine [26, 122, 123]. Nevertheless, despite this considerable progress, the available literature does not yet provide sufficiently strong evidence for actionable treatment biomarkers for ADHD in clinical settings. Biomarker studies have provided quite heterogenous findings to date, likely due to limitations of study samples, study designs and analysis methods used [3, 81], as well as the known heterogeneity of the ADHD population [10, 124]. In the following paragraphs, we highlight key directions for future research studies and methodological and practical changes required to facilitate the clinical translation of treatment biomarkers for ADHD, with the goal of promoting equitable access to personalized medicine practices for all treatment-seeking individuals.
First, there is a widespread lack of replication and out-of-sample validation of findings for most candidate predictive and monitoring/response biomarkers, with only a few notable exceptions [52]. Most studies have used small samples (e.g., N < 100 participants for MRI/EEG studies), which are unlikely to allow for reliable estimates of the associations of genetic and brain biomarkers with measures of clinical effectiveness [125, 126]. The field needs to move towards systematic replication and out-of-sample validation of promising biomarker findings in larger samples, which will be essential to guarantee that the validity of biomarkers will generalize to individuals in clinical settings in the future. This is likely to require collaborative, multi-site recruitment efforts, following examples set by biomarker research on other neurodevelopmental and psychiatric disorders [127, 128].
Second, alongside increasing sample sizes and validation efforts, future research will be needed to increase the diversity of samples with regard to age, sex, comorbidities, ethnicity, race, and geographical region. As highlighted throughout our review, most evidence to date is based on samples of children (mainly boys) from White majority backgrounds and high-income countries, typically with few psychiatric and medical co-occurring conditions, even though comorbidities are the norm in patients with ADHD [6, 129]. Several reviewed studies conducted in Western countries do not even provide information on race/ethnicity (Tables 1–5), likely suggesting the use of all-White or predominantly-White samples that are not representative of the wider population of individuals with ADHD [130]. While underrepresented minority populations have largely been excluded from biomarker research across methodologies, this issue is particularly acute for genetic research, as nearly all studies reviewed here have been conducted on White and non-Hispanic populations [131,132,133,134]. In parallel, future efforts should also increase the cultural competence of clinicians responsible for clinical assessments and treatment decisions. [135] Further, considering the clinical and etiological heterogeneity that characterizes the ADHD population [10, 124], different subgroups of individuals may display different degrees of clinical improvements and neurobiological changes in response to any given treatment. Studies investigating biomarkers of narrow aspects of ADHD symptomatology (e.g., inattentive symptoms), focusing on specific subgroups of the ADHD population (e.g., children with co-occurring ADHD and autism), and delineating data-driven clusters of individuals with ADHD will be especially useful to address this issue. The use of more heterogeneous and diverse samples and employment of inclusive research practices will be essential to ensure equitable access to future clinical applications of treatment biomarkers for people with ADHD.
Third, most studies have examined associations between specific biomarkers and treatment outcomes using correlational and group-level analyses, but any biomarker is likely to individually explain only a small amount of variance in treatment response. Classifiers and machine learning algorithms are becoming particularly popular approaches to handle high dimensionality and maximize predictive accuracy of biomarkers [3, 136]. The few studies that adopted these multivariate methods to predict treatment response at the level of individual subjects have used small sample sizes, which are known to be highly sensitive to overfitting [20, 57, 137]. Moreover, most studies did not examine whether biomarker profiles explain clinically useful variance over and above routinely-collected information such as baseline ADHD symptoms, comorbidities and neuropsychological functioning. Future studies will need to use multivariate approaches to aggregate several biomarkers across multiple units of analysis as well as clinical and demographic characteristics, in order to establish the clinical utility of promising biomarkers in combination with other more readily-available information. These combined biomarkers will then need to be tested at the individual level in independent samples, using metrics such as AUC, sensitivity, specificity, negative and positive predictive values.
Fourth, although a key aim of personalized medicine is to determine which treatments may work best out of the available options for a given patient [26, 122, 123], little work has examined the treatment-specificity of associations between brain pattern and treatment outcomes. Future research testing treatment-specific associations will be crucial for developing mechanistic models of ADHD treatments and individually tailored treatment algorithms. Such studies would also be particularly valuable to define the precise mechanisms of action of current treatment, which could then be targeted in the development of novel treatments, such as neurostimulation of the circuits sensitive to the effects of current medications. In addition, existing studies have mainly focused on associations with treatment response measured as improvements in ADHD symptoms and impairment, and more work is needed to examine whether individual differences in adverse side effects and medication tolerability can be predicted and monitored using biomarkers. Finally, quantifying biomarker thresholds for inclusion criterion or stratification of participants to treatment and subsequent testing in independent samples is a critical next step in deploying biomarkers in clinical practice and personalized medicine.
Fifth, since most of the available studies have conducted biomarker and clinical assessments only over a few weeks or months, we know very little about the clinical utility of biomarkers over longer time periods. Longitudinal work following patients with ADHD over multiple years has shown that remission from ADHD symptoms follows a highly non-linear trajectory for most patients [138], and it is not uncommon for the effects of medication to decrease or for side effects to emerge over time, despite high initial rates of response and tolerability [139, 140]. Predictive biomarkers derived before treatment allocation may thus not be indicative of longer-term treatment success [138], and future studies using longer time frames of several months or years are needed. Similarly, with regard to monitoring/response biomarkers, while most studies have focused on the therapeutic brain mechanisms of ADHD treatments at the group level, particularly with stimulants, more work is needed to explore whether individual differences in these changes act as a source of variation in treatment response. Potential clinical applications may be better informed by knowledge of how medium-term changes in biomarkers relate to treatment responses over the longer term in ADHD [138]. Thus, future studies will need to examine whether changes in brain functioning over the initial weeks of treatment predict treatment response over the longer-term, beyond the timeframe of previous studies.
Sixth, very limited work has sought to establish the reliability, robustness and reproducibility of ADHD treatment biomarkers, although these are essential biomarker characteristics that are critical for future clinical application [3, 141, 142]. The reliability of candidate neuroimaging and EEG measures has only recently been systematically evaluated [126, 143,144,145]. Findings indicate that while the reliability of certain EEG measures (particularly resting state spectral power) tends to be good in 5–10 min recording conditions [119, 146, 147], the reliability of fMRI measures becomes acceptable only with longer (i.e., over 15–20 min) recordings [145, 148]. In addition, given the flexibility in neuroimaging processing and analysis methods and the resultant large number of researcher degrees of freedom, the pre-registration of future data processing and analysis plans is essential to limit type-I errors and inflated effect sizes known to effect non-registered studies [149], as are multiverse studies in which the robustness of study findings are examined across multiple distinct pipelines and analysis strategies [150].
Finally, from a practical perspective, any neuroimaging, EEG, and genetic biomarker findings must not only be generalizable across patient subpopulations, but also across treatment sites and various testing equipment and procedures. The development of standardized biomarker testing protocols and training of healthcare professionals responsible for biomarker testing will be important challenges to face prior to clinical implementation. Further, the cost-effectiveness of brain and genetic markers is also yet to be determined from a health economics perspective, and will require pragmatic RCTs comparing the effectiveness and costs of biomarkers approaches vs. care as usual [122]. These cost-benefit considerations will be particularly salient for neuroimaging biomarkers, considering the high cost of data collection. Importantly, future efforts should also place particular attention to the acceptability of biomarker approaches for people with ADHD (i.e., participatory research and research co-production approaches [151]). This is because even the most predictive and reliable biomarker will have limited clinical utility if most patients were unwilling to undergo testing necessary to derive the biomarker. This will be especially important for biomarkers requiring more involved assessments (e.g., MRI) and measures with important ethical implications (e.g., genetics). Inclusive and participatory research practices will be crucial to maximize the feasibility and uptake of future clinical applications of treatment biomarkers by diverse groups of individuals with ADHD worldwide.
In conclusion, this article sought to highlight progress in the development of treatment biomarkers for ADHD and set clear guidance for future studies to move the field forward. Whereas most of the available research on ADHD biomarker to date has taken a primarily mechanistic approach, we hope that our recommendations will contribute to a shift toward more translational and clinically useful approaches, as well as more robust methodologies, and larger and more diverse samples. We believe that these steps will be essential to promote clinical translation of biomarker research and enhance personalized treatment decisions for diverse groups of individuals with ADHD.
References
Loo SK, Lenartowicz A, Makeig S. Research Review: use of EEG biomarkers in child psychiatry research - current state and future directions. J Child Psychol Psychiatry. 2015. https://doi.org/10.1111/jcpp.12435.
Abi-Dargham A, Horga G. The search for imaging biomarkers in psychiatric disorders. Nat Med. 2016;22:1248–55.
Uddin LQ, Dajani DR, Voorhies W, Bednarz H, Kana RK. Progress and roadblocks in the search for brain-based biomarkers of autism and attention-deficit/hyperactivity disorder. Transl Psychiatry. 2017;7:e1218.
Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126.
Michelini G, Palumbo IM, DeYoung CG, Latzman RD, Kotov R. Linking RDoC and HiTOP: a new interface for advancing psychiatric nosology and neuroscience. Clin Psychol Rev. 2021;86:102025.
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28:1059–88.
Sudre G, Mangalmurti A, Shaw P. Growing out of attention deficit hyperactivity disorder: Insights from the ‘remitted’ brain. Neurosci Biobehav Rev. 2018;94:198–209.
Kirkland AE, Holton KF. Measuring treatment response in pharmacological and lifestyle interventions using electroencephalography in ADHD: a review. Clin EEG Neurosci. 2019;50:256–66.
Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J. Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Biol Psychiatry. 2014;76:616–28.
Nigg JT, Sibley MH, Thapar A, Karalunas SL. Development of ADHD: etiology, heterogeneity, and early life course. Annu Rev Dev Psychol. 2020;2:559–83.
Rubia K, Westwood S, Aggensteiner P-M, Brandeis D. Neurotherapeutics for attention deficit/hyperactivity disorder (ADHD): a review. Cells. 2021;10:2156.
Group BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration (US): Silver Spring (MD); 2016. http://www.ncbi.nlm.nih.gov/books/NBK326791/ (accessed 23 May 2020).
Shephard E, Zuccolo PF, Idrees I, Godoy PBG, Salomone E, Ferrante C, et al. Systematic review and meta-analysis: the science of early-life precursors and interventions for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2022;61:187–226.
Pereira-Sanchez V, Castellanos FX. Neuroimaging in attention-deficit/hyperactivity disorder. Curr Opin Psychiatry. 2021;34:105–11.
Kaiser A, Aggensteiner P-M, Baumeister S, Holz NE, Banaschewski T, Brandeis D. Earlier versus later cognitive event-related potentials (ERPs) in attention-deficit/hyperactivity disorder (ADHD): a meta-analysis. Neurosci Biobehav Rev. 2020;112:117–34.
Olbrich S, van Dinteren R, Arns M. Personalized medicine: review and perspectives of promising baseline EEG biomarkers in major depressive disorder and attention deficit hyperactivity disorder. Neuropsychobiology. 2015;72:229–40.
Kim J-S, Lee KH, Hwang C-S, Kim J-W. Subcortical volumetric alterations as potential predictors of methylphenidate treatment response in youth with attention-deficit/hyperactivity disorder. J Psychiatry Neurosci. 2022;47:E11–E20.
Moreno A, Duno L, Hoekzema E, Picado M, Martin LM, Fauquet J, et al. Striatal volume deficits in children with ADHD who present a poor response to methylphenidate. Eur Child Adolesc Psychiatry. 2014;23:805–12.
Griffiths KR, Braund TA, Kohn MR, Clarke S, Williams LM, Korgaonkar MS. Structural brain network topology underpinning ADHD and response to methylphenidate treatment. Transl Psychiatry. 2021;11:1–9.
Peterson BS, Potenza MN, Wang Z, Zhu H, Martin A, Marsh R, et al. An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry. 2009;166:1286–94.
Norman LJ, Sudre G, Bouyssi-Kobar M, Sharp W, Shaw P. A longitudinal study of resting-state connectivity and response to psychostimulant treatment in ADHD. Am J Psychiatry. 2021;178:744–51.
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry. 2012;169:264–72.
Hong S-B, Harrison BJ, Fornito A, Sohn C-H, Song I-C, Kim J-W. Functional dysconnectivity of corticostriatal circuitry and differential response to methylphenidate in youth with attention-deficit/hyperactivity disorder. J Psychiatry Neurosci. 2015;40:46–57.
An L, Cao X-H, Cao Q-J, Sun L, Yang L, Zou Q-H, et al. Methylphenidate normalizes resting-state brain dysfunction in boys with attention deficit hyperactivity disorder. Neuropsychopharmacology. 2013;38:1287–95.
Arns M, van Dijk H, Luykx JJ, van Wingen G, Olbrich S. Stratified psychiatry: tomorrow’s precision psychiatry? Eur Neuropsychopharmacol. 2021;55:14–19.
Schulz KP, Bédard A-CV, Fan J, Hildebrandt TB, Stein MA, Ivanov I, et al. Striatal activation predicts differential therapeutic responses to methylphenidate and atomoxetine. J Am Acad Child Adolesc Psychiatry. 2017;56:602–9.e2.
Alegria AA, Wulff M, Brinson H, Barker GJ, Norman LJ, Brandeis D, et al. Real‐time f MRI neurofeedback in adolescents with attention deficit hyperactivity disorder. Hum Brain Mapp. 2017;38:3190–209.
Lam S-L, Criaud M, Alegria A, Barker GJ, Giampietro V, Rubia K. Neurofunctional and behavioural measures associated with fMRI-neurofeedback learning in adolescents with Attention-Deficit/Hyperactivity Disorder. NeuroImage Clin. 2020;27:102291.
Criaud M, Wulff M, Alegria AA, Barker GJ, Giampietro V, Rubia K. Increased left inferior fronto-striatal activation during error monitoring after fMRI neurofeedback of right inferior frontal cortex in adolescents with attention deficit hyperactivity disorder. NeuroImage Clin. 2020;27:102311. 2.
Lukito S, Norman L, Carlisi C, Radua J, Hart H, Simonoff E, et al. Comparative meta-analyses of brain structural and functional abnormalities during cognitive control in attention-deficit/hyperactivity disorder and autism spectrum disorder. Psychol Med. 2020;50:894–919.
Norman LJ, Carlisi C, Lukito S, Hart H, Mataix-Cols D, Radua J, et al. Structural and functional brain abnormalities in attention-deficit/hyperactivity disorder and obsessive-compulsive disorder: a comparative meta-analysis. JAMA Psychiatry. 2016;73:815–25.
Loo SK, Makeig S. Clinical utility of EEG in attention-deficit/hyperactivity disorder: a research update. Neurotherapeutics. 2012;9:569–87.
Jeste SS, Frohlich J, Loo SK. Electrophysiological biomarkers of diagnosis and outcome in neurodevelopmental disorders. Curr Opin Neurol. 2015;28:110–6.
Sari Gokten E, Tulay EE, Beser B, Elagoz Yuksel M, Arikan K, Tarhan N, et al. Predictive Value of Slow and Fast EEG Oscillations for Methylphenidate Response in ADHD. Clin EEG Neurosci. 2019;50:332–8.
Ogrim G, Hestad KA, Kropotov J, Sandvik L, Candrian G, Brunner JF. Predicting the clinical outcome of stimulant medication in pediatric attention-deficit/hyperactivity disorder: data from quantitative electroencephalography, event-related potentials, and a go/no-go test. Neuropsychiatr Dis Treat. 2014;10:231–42.
Bellato A, Arora I, Hollis C, Groom MJ. Is autonomic nervous system function atypical in attention deficit hyperactivity disorder (ADHD)? A systematic review of the evidence. Neurosci Biobehav Rev. 2020;108:182–206.
Arns M, Vollebregt MA, Palmer D, Spooner C, Gordon E, Kohn M, et al. Electroencephalographic biomarkers as predictors of methylphenidate response in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2018;28:881–91.
Arns M, Conners CK, Kraemer HC. A decade of EEG theta/beta ratio research in ADHD: a meta-analysis. J Atten Disord. 2013;17:374–83.
Arns M, Loo SK, Sterman MB, Heinrich H, Kuntsi J, Asherson P, et al. Editorial perspective: how should child psychologists and psychiatrists interpret FDA device approval? Caveat emptor. J Child Psychol Psychiatr. 2016;57:656–8.
Sangal RB, Sangal JM. Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response. Clin Neurophysiol. 2006;117:1996–2006.
Ogrim G, Kropotov JD. Predicting clinical gains and side effects of stimulant medication in pediatric attention-deficit/hyperactivity disorder by combining measures From qEEG and ERPs in a cued GO/NOGO task. Clin EEG Neurosci. 2019;50:34–43.
Young ES, Perros P, Price GW, Sadler T. Acute challenge ERP as a prognostic of stimulant therapy outcome in attention-deficit hyperactivity disorder. Biol Psychiatry. 1995;37:25–33.
Chiarenza GA, Chabot R, Isenhart R, Montaldi L, Chiarenza MP, Torto MGL, et al. The quantified EEG characteristics of responders and non-responders to long-term treatment with atomoxetine in children with attention deficit hyperactivity disorders. Int J Psychophysiol. 2016;104:44–52.
Griffiths KR, Jurigova BG, Leikauf JE, Palmer D, Clarke SD, Tsang TW, et al. A signature of attention-elicited electrocortical activity distinguishes response from non-response to the non-stimulant atomoxetine in children and adolescents with ADHD. J Atten Disord. 2019;23:744–53.
Sangal RB, Sangal JM. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine. Clin Neurophysiol. 2005;116:640–7.
Leuchter AF, McGough JJ, Korb AS, Hunter AM, Glaser PEA, Deldar A, et al. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project. J Psychiatr Res. 2014;54:11–18.
Singh G, Arun P, Das S, Kaur D. Can EEG predict response to atomoxetine in attention deficit hyperactivity disorder at 1 Week? J Atten Disord. 2021;25:758–67.
Loo SK, Salgari GC, Ellis A, Cowen J, Dillon A, McGough JJ. Trigeminal nerve stimulation for attention-deficit/hyperactivity disorder: cognitive and electroencephalographic predictors of treatment response. J Am Acad Child Adolesc Psychiatry. 2021;60:856–86.e1.
Krepel N, Egtberts T, Sack AT, Heinrich H, Ryan M, Arns M. A multicenter effectiveness trial of QEEG-informed neurofeedback in ADHD: Replication and treatment prediction. Neuroimage Clin. 2020;28:102399.
Bazanova OM, Auer T, Sapina EA. On the efficiency of individualized theta/beta ratio neurofeedback combined with forehead EMG training in ADHD Children. Front Hum Neurosci. 2018;12:3.
Voetterl H, van Wingen G, Michelini G, Griffiths KR, Gordon E, DeBeus R, et al. Brainmarker-I differentially predicts remission to various attention-deficit/hyperactivity disorder treatments: a discovery, transfer, and blinded validation study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022;S2451-9022:00046–5.
Schönenberg M, Wiedemann E, Schneidt A, Scheeff J, Logemann A, Keune PM, et al. Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial. Lancet Psychiatry. 2017;4:673–84.
Van Doren J, Arns M, Heinrich H, Vollebregt MA, Strehl U, Loo K, et al. Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2019;28:293–305.
Neurofeedback Collaborative Group. Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up. J Am Acad Child Adolesc Psychiatry. 2020. https://doi.org/10.1016/j.jaac.2020.07.906.
Luo X, Guo X, Zhao Q, Zhu Y, Chen Y, Zhang D, et al. A randomized controlled study of remote computerized cognitive, neurofeedback, and combined training in the treatment of children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2022. https://doi.org/10.1007/s00787-022-01956-1.
Michelini G, Lenartowicz A, Vera JD, Bilder RM, McGough JJ, McCracken JT, et al. Electrophysiological and clinical predictors of methylphenidate, guanfacine, and combined treatment outcomes in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2022;S0890-8567:01229–1.
Arns M, Gunkelman J, Breteler M, Spronk D. EEG phenotypes predict treatment outcome to stimulants in children with ADHD. J Integr Neurosci. 2008;07:421–38.
Gul MK, Sener EF, Onal MG, Demirci E. Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: From response to side effects in children with ADHD. J Psychopharmacol. 2022;36:715–722. https://doi.org/10.1177/02698811211015245.
Myer NM, Boland JR, Faraone SV. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry. 2018;23:1929–36.
Kendler KS. What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn. Mol Psychiatry. 2013;18:1058–66.
Pagerols M, Richarte V, Sánchez-Mora C, Rovira P, Soler Artigas M, Garcia-Martínez I, et al. Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder. Sci Rep. 2018;8:1881.
Zhong Y, Yang B, Su Y, Qian Y, Cao Q, Chang S, et al. The association with quantitative response to attention-deficit/hyperactivity disorder medication of the previously identified neurodevelopmental network genes. J Child Adolesc Psychopharmacol. 2020;30:348–54.
Brikell I, Wimberley T, Albiñana C, Pedersen EM, Vilhjálmsson BJ, Agerbo E, et al. Genetic, clinical, and sociodemographic factors associated with stimulant treatment outcomes in ADHD. Am J Psychiatry 2021; https://doi.org/10.1176/appi.ajp.2020.20121686.
Elia J, Glessner JT, Wang K, Takahashi N, Shtir CJ, Hadley D, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011;44:78–84.
Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, et al. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018;9:4.
Hegvik T-A, Waløen K, Pandey SK, Faraone SV, Haavik J, Zayats T. Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment. Mol Psychiatry. 2021;26:4004–15.
Yu G, Li G-F, Markowitz JS. Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016;26:314–26.
Bouziane C, Filatova OG, Schrantee A, Caan MW, Vos FM, Reneman L. White matter by diffusion MRI following methylphenidate treatment: a randomized control trial in males with attention-deficit/hyperactivity disorder. Radiology. 2019;293:186–92.
Walhovd KB, Amlien I, Schrantee A, Rohani DA, Groote I, Bjørnerud A, et al. Methylphenidate effects on cortical thickness in children and adults with attention-deficit/hyperactivity disorder: a randomized clinical trial. Am J Neuroradiol. 2020;41:758–65.
van Elst LT, Maier S, Klöppel S, Graf E, Killius C, Rump M, et al. The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial. J Psychiatry Neurosci. 2016;41:422–30.
Rubia K, Halari R, Cubillo A, Mohammad A-M, Brammer M, Taylor E. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology. 2009;57:640–52.
Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer MJ, Simmons A, et al. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cereb Cortex. 2014;24:174–85.
Smith A, Cubillo A, Barrett N, Giampietro V, Simmons A, Brammer M, et al. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination. Biol Psychiatry. 2013;74:615–22.
Kowalczyk OS, Cubillo AI, Smith A, Barrett N, Giampietro V, Brammer M, et al. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. Eur Neuropsychopharmacol. 2019;29:1102–16.
Rubia K, Halari R, Christakou A, Taylor E. Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate. Philos Trans R Soc B Biol Sci. 2009;364:1919–31.
Rubia K, Halari R, Cubillo A, Smith AB, Mohammad A-M, Brammer M, et al. Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naive boys with attention-deficit hyperactivity disorder. Neuropsychopharmacol. 2011;36:1575–86.
Liddle EB, Hollis C, Batty MJ, Groom MJ, Totman JJ, Liotti M, et al. Task‐related default mode network modulation and inhibitory control in ADHD: Effects of motivation and methylphenidate. J Child Psychol Psychiatry. 2011;52:761–71.
Silk TJ, Malpas C, Vance A, Bellgrove MA. The effect of single-dose methylphenidate on resting-state network functional connectivity in ADHD. Brain imaging behav. 2017;11:1422–31.
Schrantee A, Mutsaerts H, Bouziane C, Tamminga HGH, Bottelier MA, Reneman L. The age-dependent effects of a single-dose methylphenidate challenge on cerebral perfusion in patients with attention-deficit/hyperactivity disorder. NeuroImage Clin. 2017;13:123–9.
Pereira-Sanchez V, Franco AR, Vieira D, de Castro-Manglano P, Soutullo C, Milham MP, et al. Systematic review: medication effects on brain intrinsic functional connectivity in patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2021;60:222–35.
Wang Y, Kessel E, Lee S, Hong S, Raffanello E, Hulvershorn LA, et al. Causal effects of psychostimulants on neural connectivity: a mechanistic, randomized clinical trial. J Child Psychol Psychiatry. 2022. https://doi.org/10.1111/jcpp.13585.
Mizuno Y, Cai W, Supekar K, Makita K, Takiguchi S, Tomoda A, et al. Methylphenidate remediates aberrant brain network dynamics in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. NeuroImage. 2022;257:119332.
Cortese S, Aoki YY, Itahashi T, Castellanos FX, Eickhoff SB. Systematic review and meta-analysis: resting state functional magnetic resonance imaging studies of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2021;60:61–75.
Yang Z, Kelly C, Castellanos FX, Leon T, Milham MP, Adler LA. Neural correlates of symptom improvement following stimulant treatment in adults with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26:527–36.
Yoo JH, Kim D, Choi J, Jeong B. Treatment effect of methylphenidate on intrinsic functional brain network in medication-naïve ADHD children: a multivariate analysis. Brain Imaging Behav. 2018;12:518–31.
Lin H-Y, Gau SS-F. Atomoxetine treatment strengthens an anti-correlated relationship between functional brain networks in medication-naïve adults with attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled clinical trial. Int J Neuropsychopharmacol. 2016;19:pyv094.
Shang CY, Yan CG, Lin HY, Tseng WY, Castellanos FX, Gau SS. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. Psychol Med. 2016;46:3173–85.
Schulz KP, Fan J, Bédard A-CV, Clerkin SM, Ivanov I, Tang CY, et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2012;69:952.
Rubia K, Criaud M, Wulff M, Alegria A, Brinson H, Barker G, et al. Functional connectivity changes associated with fMRI neurofeedback of right inferior frontal cortex in adolescents with ADHD. NeuroImage. 2019;188:43–58.
Loo SK, Teale PD, Reite ML. EEG correlates of methylphenidate response among children with ADHD: a preliminary report. Biol Psychiatry. 1999;45:1657–60.
Loo SK, Hopfer C, Teale PD, Reite ML. EEG correlates of methylphenidate response in ADHD: association with cognitive and behavioral measures. J Clin Neurophysiol. 2004;21:457–64.
Lubar JF, White JN, Swartwood MO, Swartwood JN. Methylphenidate effects on global and complex measures of EEG. Pediatr Neurol. 1999;21:633–7.
Song DH, Shin DW, Jon DI, Ha EH. Effects of methylphenidate on quantitative EEG of boys with attention-deficit hyperactivity disorder in continuous performance test. Yonsei Med J. 2005;46:34–41.
Michelini G, Kitsune GL, Cheung CH, Brandeis D, Banaschewski T, Asherson P, et al. Attention-deficit/hyperactivity disorder remission is linked to better neurophysiological error detection and attention-vigilance processes. Biol Psychiatry. 2016;80:923–32.
Groom MJ, Scerif G, Liddle PF, Batty MJ, Liddle EB, Roberts KL, et al. Effects of motivation and medication on electrophysiological markers of response inhibition in children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2010;67:624–31.
Verbaten MN, Overtoom CC, Koelega HS, Swaab-Barneveld H, van der Gaag RJ, Buitelaar J, et al. Methylphenidate influences on both early and late ERP waves of ADHD children in a continuous performance test. J Abnorm Child Psychol. 1994;22:561–78.
Groom MJ, Liddle EB, Scerif G, Liddle PF, Batty MJ, Liotti M, et al. Motivational incentives and methylphenidate enhance electrophysiological correlates of error monitoring in children with attention deficit/hyperactivity disorder. J Child Psychol Psychiatry. 2013;54:836–45.
Barry RJ, Clarke AR, Hajos M, McCarthy R, Selikowitz M, Bruggemann JM. Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder. Neuropharmacol. 2009;57:702–7.
Clarke AR, Barry RJ, Johnstone S. Resting state EEG power research in attention-deficit/hyperactivity disorder: a review update. Clin Neurophysiol. 2020;131:1463–79.
Michelini G, Salmastyan G, Vera JD, Lenartowicz A. Event-related brain oscillations in attention-deficit/hyperactivity disorder (ADHD): a systematic review and meta-analysis. Int J Psychophysiol. 2022;174:29–42.
Bresnahan SM, Barry RJ, Clarke AR, Johnstone SJ. Quantitative EEG analysis in dexamphetamine-responsive adults with attention-deficit/hyperactivity disorder. Psychiatry Res. 2006;141:151–9.
Janssen TWP, Bink M, Geladé K, van Mourik R, Maras A, Oosterlaan J. A randomized controlled trial into the effects of neurofeedback, methylphenidate, and physical activity on EEG power spectra in children with ADHD. J Child Psychol Psychiatry. 2016;57:633–44.
Clarke AR, Barry RJ, Bond D, McCarthy R, Selikowitz M. Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder. Psychopharmacology. 2002;164:277–84.
Clarke AR, Barry RJ, McCarthy R, Selikowitz M, Brown CR, Croft RJ. Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder predominantly inattentive type. Int J Psychophysiol. 2003;47:129–37.
Isiten HN, Cebi M, Kaya BS, Metin B, Tarhan N. Medication effects on EEG Biomarkers in attention-deficit/hyperactivity disorder. Clin EEG Neurosci. 2017;48:246–50.
Hermens DF, Williams LM, Clarke S, Kohn M, Cooper N, Gordon E. Responses to methylphenidate in adolescent AD/HD: Evidence from concurrently recorded autonomic (EDA) and central (EEG and ERP) measures. Int J Psychophysiol. 2005;58:21–33.
Skirrow C, McLoughlin G, Banaschewski T, Brandeis D, Kuntsi J, Asherson P. Normalisation of frontal theta activity following methylphenidate treatment in adult attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2015;25:85–94.
Loo SK, Bilder RM, Cho AL, Sturm A, Cowen J, Walshaw P, et al. Effects of d-methylphenidate, guanfacine, and their combination on electroencephalogram resting state spectral power in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2016;55:674–82.e1.
Janssen TWP, Bink M, Geladé K, van Mourik R, Maras A, Oosterlaan J. A randomized controlled trial investigating the effects of neurofeedback, methylphenidate, and physical activity on event-related potentials in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26:344–53.
Peisch V, Rutter T, Wilkinson CL, Arnett AB. Sensory processing and P300 event-related potential correlates of stimulant response in children with attention-deficit/hyperactivity disorder: a critical review. Clin Neurophysiol. 2021;132:953–66.
Rubinson M, Horowitz I, Naim-Feil J, Gothelf D, Levit-Binnun N, Moses E. Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study. PLoS ONE. 2019;14:e0217383.
Aasen IE, Øgrim G, Kropotov J, Brunner JF. Methylphenidate selectively modulates one sub-component of the no-go P3 in pediatric ADHD medication responders. Biol Psychol. 2018;134:30–8.
McGough JJ, Sturm A, Cowen J, Tung K, Salgari GC, Leuchter AF, et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019;58:403–11.e3.
Aggensteiner P-M, Albrecht B, Strehl U, Wörz S, Ruckes C, Freitag CM, et al. Can neurophysiological markers of anticipation and attention predict ADHD severity and neurofeedback outcomes? Biol Psychol. 2021;165:108169.
Aldemir R, Demirci E, Bayram AK, Canpolat M, Ozmen S, Per H, et al. EvaluatioN of two types of drug treatment with QEEG in children with ADHD. Transl Neurosci. 2018;9:106–16.
Kratz O, Studer P, Baack J, Malcherek S, Erbe K, Moll GH, et al. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:81–9.
Michelini G, Lenartowicz A, Bilder RM, McGough JJ, McCracken JT, Loo SK. Methylphenidate, guanfacine, and combined treatment effects on EEG correlates of spatial working memory deficits in ADHD. J Am Acad Child Adolesc Psychiatry. 2022;S0890-8567:01228–X.
Lenartowicz A, Truong H, Salgari GC, Bilder RM, McGough J, McCracken JT, et al. Alpha modulation during working memory encoding predicts neurocognitive impairment in ADHD. J Child Psychol Psychiatry. 2019;60:917–26.
Bozhilova N, Cooper R, Kuntsi J, Asherson P, Michelini G. Electrophysiological correlates of spontaneous mind wandering in attention-deficit/hyperactivity disorder. Behav Brain Res. 2020;391:112632.
Janssen TWP, Geladé K, Bink M, van Mourik R, Twisk JWR, Maras A, et al. Long-term effects of theta/beta neurofeedback on EEG power spectra in children with attention deficit hyperactivity disorder. Clin Neurophysiol. 2020;131:1332–41.
Cortese S. Setting the foundations of developmental precision psychiatry for ADHD. Am J Psychiatry. 2021;178:677–9.
Posner J. The role of precision medicine in child psychiatry: what can we expect and when? J Am Acad Child Adolesc Psychiatry. 2018;57:813–7.
Loo SK, McGough JJ, McCracken JT, Smalley SL. Parsing heterogeneity in attention-deficit hyperactivity disorder using EEG-based subgroups. J Child Psychol Psychiatry. 2017. https://doi.org/10.1111/jcpp.12814.
Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosc. 2013;14:365–76.
Marek S, Tervo-Clemmens B, Calabro FJ, Montez DF, Kay BP, Hatoum AS, et al. Reproducible brain-wide association studies require thousands of individuals. Nature. 2022;603:654–60.
Shic F, Naples AJ, Barney EC, Chang SA, Li B, McAllister T, et al. The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials. Mol Autism. 2022;13:15.
Whitton AE, Webb CA, Dillon DG, Kayser J, Rutherford A, Goer F, et al. Pretreatment rostral anterior cingulate cortex connectivity with salience network predicts depression recovery: findings from the EMBARC randomized clinical trial. Biol Psychiatry. 2019;85:872–80.
Kittel-Schneider S, Arteaga-Henriquez G, Vasquez AA, Asherson P, Banaschewski T, Brikell I, et al. Non-mental diseases associated with ADHD across the lifespan: fidgety philipp and pippi longstocking at risk of multimorbidity? Neurosci Biobehav Rev. 2022;132:1157–80.
Charpentier CJ, Faulkner P, Pool ER, Ly V, Tollenaar MS, Kluen LM, et al. How representative are neuroimaging samples? Large-scale evidence for trait anxiety differences between fMRI and behaviour-only research participants. Soc Cogn Affect Neurosci. 2021;16:1057–70.
Etienne A, Laroia T, Weigle H, Afelin A, Kelly SK, Krishnan A, et al. Novel electrodes for reliable EEG recordings on coarse and curly hair. Annu Int Conf IEEE Eng Med Biol Soc. 2020;2020:6151–4.
Ruan Y, Lin Y-F, Feng Y-CA, Chen C-Y, Lam M, Guo Z, et al. Improving polygenic prediction in ancestrally diverse populations. Nat Genet. 2022;54:573–80.
Goldfarb MG, Brown DR. Diversifying participation: the rarity of reporting racial demographics in neuroimaging research. Neuroimage. 2022;254:119122.
Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51:584–91.
Slobodin O, Masalha R. Challenges in ADHD care for ethnic minority children: a review of the current literature. Transcult Psychiatry. 2020;57:468–83.
Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3:223–30.
Kim J-W, Sharma V, Ryan ND. Predicting methylphenidate response in ADHD using machine learning approaches. International Journal of Neuropsychopharmacology. 2015;18:pyv052.
Sibley MH, Arnold LE, Swanson JM, Hechtman LT, Kennedy TM, Owens E, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Am J Psychiatry. 2021;179:142–51.
Coghill D, Banaschewski T, Cortese S, Asherson P, Brandeis D, Buitelaar J, et al. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry. 2021. https://doi.org/10.1007/s00787-021-01871-x.
Cortese S. Debate: are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? J Am Acad Child Adolesc Psychiatry. 2019;58:936.
Elliott ML, Knodt AR, Hariri AR. Striving toward translation: strategies for reliable fMRI measurement. Trends Cogn Sci. 2021;25:776–87.
Milham MP, Vogelstein J, Xu T. Removing the reliability bottleneck in functional magnetic resonance imaging research to achieve clinical utility. JAMA Psychiatry. 2021;78:587–8.
Ethridge P, Weinberg A. Psychometric properties of neural responses to monetary and social rewards across development. Int J Psychophysiol. 2018;132:311–22.
Elliott ML, Knodt AR, Ireland D, Morris ML, Poulton R, Ramrakha S, et al. What Is the test-retest reliability of common task-functional MRI measures? new empirical evidence and a meta-analysis. Psychol Sci. 2020;31:792–806.
Nentwich M, Ai L, Madsen J, Telesford QK, Haufe S, Milham MP, et al. Functional connectivity of EEG is subject-specific, associated with phenotype, and different from fMRI. NeuroImage. 2020;218:117001.
Cannon RL, Baldwin DR, Shaw TL, Diloreto DJ, Phillips SM, Scruggs AM, et al. Reliability of quantitative EEG (qEEG) measures and LORETA current source density at 30 days. Neurosci Lett. 2012;518:27–31.
Rietdijk WJR, Franken IHA, Thurik AR. Internal consistency of event-related potentials associated with cognitive control: N2/P3 and ERN/Pe. PLoS ONE. 2014 https://doi.org/10.1371/journal.pone.0102672.
Yang Z, Telesford QK, Franco AR, Lim R, Gu S, Xu T, et al. Measurement reliability for individual differences in multilayer network dynamics: cautions and considerations. Neuroimage. 2021;225:117489.
Schäfer T, Schwarz MA. The meaningfulness of effect sizes in psychological research: differences between sub-disciplines and the impact of potential biases. Front Psychol. 2019;10:813.
Dafflon J, Da Costa PF, Váša F, Monti RP, Bzdok D, Hellyer PJ, et al. Neuroimaging: into the Multiverse. bioRxiv. 2020. https://doi.org/10.1101/2020.10.29.359778.
Honeycutt C, Sleath B, Bush PJ, Campbell W, Tudor G. Physician use of a participatory decision-making style with children with ADHD and their parents. Patient Educ Couns. 2005;57:327–32.
Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer M, Simmons A, et al. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory. Psychol Med. 2014;44:633–46.
Rubia K, Halari R, Mohammad A-M, Taylor E, Brammer M. Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;70:255–62.
Acknowledgements
This work is supported by National Institute of Mental Health (NIMH) grants (R01MH116268 and RO1MH126041 to SKL), by a Klingenstein Third Generation Foundation fellowship (20212999 to GM) and by the intramural research programs of the National Institute of Mental Health and the National Human Genome Research Institute (ZIAHG200378 to PS). This work reflects the views of the authors and may not reflect the opinions or views of NIH or other funders.
Author information
Authors and Affiliations
Contributions
SL conceived and structured the manuscript. GM, LN, PS, and SL wrote the manuscript. GM and LN conducted the literature search. SL revised the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Michelini, G., Norman, L.J., Shaw, P. et al. Treatment biomarkers for ADHD: Taking stock and moving forward. Transl Psychiatry 12, 444 (2022). https://doi.org/10.1038/s41398-022-02207-2
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41398-022-02207-2
This article is cited by
-
Cortical alterations associated with lower response to methylphenidate in adults with ADHD
Nature Mental Health (2024)